TCR sequences unique to LMP-TC product expanded after infusion and were maintained in responders. Patient A3, with CR and with TCR sequences unique to product persistent at 11 months (A); patient A4, CR with TCR sequences until 8 months (B); patient A7, PR with sequences present until 17 months (C); patient C2, with PD, had declining unique TCR sequences at second follow-up time point, and patient received further therapy with CAR-T. After CAR-T, evidence of expansion of novel TCR sequences were again evident (D). Diversity of TCR clones present in LMP-TC products (E). CAR-T, chimeric antigen receptor T-cell therapy.